Introduction:
Leading healthcare company has received approval from the SEC-CDSCO to conduct Phase III clinical trials for Cenobamate Tablets, an advanced anti-seizure medication. The trials will assess efficacy and safety, aiming to provide a reliable treatment for epilepsy patients in India.
Also Read: Defence stock jumps 4% after acquiring 45.33% paid up capital in Bhairav Robotics
Share price movement of Bajaj Healthcare:
On March 19, 2025, Bajaj Healthcare Limited opened at ₹680.00, rising 0.91% from its previous close of ₹673.85. The stock hit a high of ₹744.90 (10.54%) and a low of ₹645.60. By 3:00 PM, it traded at ₹705.00, up 4.62%, with a market cap of ₹2,226.62 crore.
Bajaj Healthcare Gains SEC-CDSCO Approval:
Bajaj Healthcare Limited (BHL) has secured approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets. The trials will assess the drug’s efficacy, safety, and tolerability.
Cenobamate is an advanced anti-seizure medication designed to treat partial-onset seizures in adults. It helps regulate excessive neuronal activity, reducing seizure frequency and improving patient outcomes. Bajaj Healthcare aims to introduce a safe and effective treatment option for epilepsy patients in India.
Also Read: The C-Suite Women: Arundhati Bhattacharya & Her Path to Success
The upcoming Phase III trials mark a crucial step before regulatory approval. Bajaj Healthcare plans to manufacture the active pharmaceutical ingredient (API) in-house, ensuring quality control. Upon successful trials, the company will seek final approval for commercial launch in India.
Recent news on Bajaj Healthcare:
As of February 11, 2025, Bajaj Healthcare Limited reported a net profit of ₹11.7 crore in Q3 FY25, reversing a loss of ₹2.2 crore last year. Revenue rose 13.1% to ₹122.8 crore, driven by strong API and bulk drug demand.
Ace investor holding in Bajaj Healthcare:
Vanaja Sundar Iyer
Vanaja Sundar Iyer holds a 2.06% stake in Bajaj Healthcare Ltd with 650,888 shares valued at ₹46.0 crore. Her significant investment reflects confidence in the company’s growth prospects amid its advancements in the pharmaceutical sector.
Stock performance of Bajaj Healthcare for Period of 1 week, 6 months, and 1 year:
Bajaj Healthcare Limited has delivered strong returns, gaining 5.11% in a week, 78.5% over six months, and an impressive 124% in a year. The company’s robust growth reflects investor confidence and steady performance in the pharmaceutical sector.
Also Read: Steel stocks jump up to 7% after DGTR recommends 12% temporary tax to curb imports
Shareholding pattern of Bajaj Healthcare:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 59.20% | 59.20% | 67.70% |
| FII | 1.00% | 1.10% | 0.00% |
| DII | 2.40% | 2.00% | 0% |
| Public | 37.50% | 37.80% | 32.30% |
About Bajaj Healthcare:
Bajaj Healthcare Limited (NSE: BAJAJHCARE) is a leading manufacturer of APIs, intermediates, formulations, and nutraceuticals. Established in 1993, it operates state-of-the-art facilities and has a strong global presence across Europe, the USA, Australia, the Middle East, and South America.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
